PARP inhibitor-related upregulation of PD-L1 expression in breast cancer cell lines and animal models appears to occur by knocking out GSK3β activity, which significantly increases PD-L1 expression and resistance to PARP inhibition. This evidence concerns the gene PARP1 and breast cancer.